Skyepharma reported 2015 results and a proposed merger with Vectura on 16th March. The enlarged group would have significant expertise across three inhalation delivery platforms (pMDI, DPI and nebulisers). The proposed terms of the deal offers Skyepharma shareholders 2.7977 Vectura shares per Skyepharma share, currently valuing Skyepharma at c.£470.8m. Skyepharma’s shareholders will own 41.75% of the enlarged group before any of the partial cash alternative (up to £70m) is paid. Skyepharma repor ....
23 Mar 2016
2015 results; proposed merger with Vectura
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2015 results; proposed merger with Vectura
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
23 Mar 2016 -
Author:
N+1 Singer Team -
Pages:
9
Skyepharma reported 2015 results and a proposed merger with Vectura on 16th March. The enlarged group would have significant expertise across three inhalation delivery platforms (pMDI, DPI and nebulisers). The proposed terms of the deal offers Skyepharma shareholders 2.7977 Vectura shares per Skyepharma share, currently valuing Skyepharma at c.£470.8m. Skyepharma’s shareholders will own 41.75% of the enlarged group before any of the partial cash alternative (up to £70m) is paid. Skyepharma repor ....